By Category

Health Canada Labeling and packaging findings

by this agency in this category 221 findings drawn from 197 published documents. The most recent cases are below; the full set is in search.

See all Health Canada Labeling and packaging findings

Companies with the most findings

Beauty Mark Solutions Inc4Estée Lauder Cosmetics Ltd.4Accord Healthcare Inc.3Capcium Inc.3Delta Pharma Inc.3

Recent findings

Health Canada Quadra Chemicals Ltd. 2026-07-14

The importer did not ensure that the foreign sites use to fabricate, package/label, or test drug products met the requirements described in Guidance on Evidence to Demonstrate Drug GMP Compliance of Foreign Sites (GUI-0080).

View official source
Health Canada Alk-Abello Pharmaceuticals Inc 2026-06-16

The importer did not ensure that the foreign sites use to fabricate, package/label, or test drug products met the requirements described in Guidance on Evidence to Demonstrate Drug GMP Compliance of Foreign Sites (GUI-0080).

View official source
Health Canada Element Materials Technology Life Sciences Canada Inc. 2026-06-02

The handling of standard operating procedures for good manufacturing practices was inadequate. The quality agreement outlining the responsibilities for fabricating, packaging or labelling, and/or testing was inadequate.

See every finding in this document View official source
Health Canada Estée Lauder Cosmetics Ltd. 2026-05-06

The importer did not ensure that the foreign sites use to fabricate, package/label, or test drug products met the requirements described in Guidance on Evidence to Demonstrate Drug GMP Compliance of Foreign Sites (GUI-0080).

See every finding in this document View official source
Health Canada HFC Prestige International Canada, Inc. 2026-04-21

The positive identification of each batch of drug after the packaging and/or after it was received on the importer's premises was inadequate.

View official source
Health Canada Salient Medical Solutions Inc. 2026-04-20

The importer did not ensure that the foreign sites use to fabricate, package/label, or test drug products met the requirements described in Guidance on Evidence to Demonstrate Drug GMP Compliance of Foreign Sites (GUI-0080).

See every finding in this document View official source

Other agencies

US FDAHealth Canada

These findings are a record of the moment each document was published. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out — do not read them as the current state; check the regulator's official announcements for the latest status. Counts are measured from public data as of 2026-09-04, and findings are extracted automatically from the regulator's published documents. “View official source” on each case links directly to that document.